- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05224219
Modified Preloaded System for Renal Arteries in Fenestrated Endografting (MPSRA) (MPSRA)
Modified Preloaded System for Renal Arteries in Fenestrated Endografting
Descripción general del estudio
Estado
Descripción detallada
Thoracoabdominal aortic aneurysm (TAAA) and complex abdominal aortic aneurysms (AAA) represents an evolving pathology that involves to varying degrees both the descending thoracic aorta and the abdominal aorta. These aneurysms, according to their localization and involvement in the thoracic and abdominal aorta, have been classified according to Crawford into 4 groups (I-IV) for the TAAA and in pararenal/juxtarenal (p/j-AAA) for AAA when a standard endovascular repair is not possible.
The prevalence of these pathologies is currently not well known, but high mortality rates are reported in the population carrying TAAAs and j/p-AAAs that have not undergone surgical treatment, most of which are due to aortic rupture.
Among of the main complications related to TAAA endovascular repair and to complex AAA we can account spinal cord ischemia, lower leg ischemia and logo-operative times, that all can contribute to decrease overall technical and clinical success.
A particular subgroup of TAAAs is represented by post-dissection thoracoabdominal aneurysms (PDTAA), which represents an evolving pathology and one of the main chronic complications in outcomes of acute chronic dissection. In these particular subset of patients, as well as in patient with highly calcified and hostile accesses, the risk of post-operative spinal cord ischemia is higher and the availability of both iliac access navigability is not always possible, leading to technical failure, intraoperative complications and need for adjunctive invasive procedures in high surgical risk patients.
The fenestrated and branched endoprostheses (F/B-EVAR) represent a technology that is now firmly used for the treatment of thoraco-abdominal degenerative aneurysmal pathology in superspecialized centers. Recently, the technology with F/B-EVAR has also been used in the treatment of PDTAA, IMH and PAU, showing satisfactory results. This experience has been carried out in some centers, in the absence, however, of a wider and generalized experience. All these type of endografts are custom-made devices, requiring therefore a lading time for production and delivering before being implanted into the specific patient.
In order to overcome main drawbacks of these procedures, such us long operating time due to fenestrations and vessels cannulation, to avoid bilateral lower limbs ischemia due to large bore introducer sheaths and to accomplish successful delivery even in patient without navigability of both iliac accesses, a modified preloaded system for renal arteries has been developed by Cook (Cook Medical, Bloomington, IN, USA).
The aim of the study is to evaluate in a prospective single center study observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries developed by Cook Medical with bi-port handle system in the field of fenestrated endografting during the routine treatment of thoraco-abdominal and paravisceral abdominal aortic pathologies.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Enrico Gallitto, MD, PhD
- Número de teléfono: +393330512143288
- Correo electrónico: enrico.gallitto@gmail.com
Ubicaciones de estudio
-
-
Emilia Romagna
-
Bologna, Emilia Romagna, Italia, 40138
- Reclutamiento
- University of Bologna
-
Contacto:
- Enrico Gallitto, MD, PhD
- Número de teléfono: +390512143288
- Correo electrónico: enrico.gallitto@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Diagnosis of thoraco-abdominal or complex abdominal aortic aneurysm confirmed by a Computed tomography Angiography (CTA).
- Etiologies will be degenerative aneurysms, inflammatory aneurysms, chronic post-dissectional aneurysms, penetrating aortic ulcers, failure of prior surgical or endovascular repair.
- Elective aneurysmal repair of patient with maximum diameter greater than 55 mm, or fast growing, or symptomatic aneurysms.
- Endovascular repair performed using custom-made fenestrated and/or branched endografting with presence of modified preloaded system with modified handle and preloaded catheters for visceral vessels cannulation.
Exclusion Criteria:
- Patients submitted to advanced fenestrated and branched endovascular repair with other grafts besides the Cook Medical custom-made endograft or without modified handle preloaded delivery system.
- Physician-modified devices
- Patient treated with hybrid and/or open technique as well as parallel grafts (such as chimney/snorkel/periscope)
- Patient treated as emergent/urgent patients or aneurysmal rupture
- Patient who can not wait for the lead time required for endograft production and delivery.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Technical Success
Periodo de tiempo: Intra-operative final completion angiography.
|
Successful deployment of custom-made modified endograft, target vessel patency and aneurysm exclusion, in absence of intra-operative mortality.
|
Intra-operative final completion angiography.
|
Mortality
Periodo de tiempo: Within the first 30-days from the procedure.
|
Assessment of mortality related to procedure
|
Within the first 30-days from the procedure.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Cardiovascular Adverse Events
Periodo de tiempo: Within the first 30-days from the procedure.
|
Cardiopulmonary and renal events related to the procedure.
|
Within the first 30-days from the procedure.
|
Neurologic Adverse Events
Periodo de tiempo: Within the first 30-days from the procedure.
|
Incidence of Spinal Cord Ischemia (transient/permanent) and Stroke
|
Within the first 30-days from the procedure.
|
Vessel Instability
Periodo de tiempo: Within the first 30-days from the procedure.
|
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
|
Within the first 30-days from the procedure.
|
Rate of early reintervention
Periodo de tiempo: Within the first 30-days from the procedure.
|
Any re-intervention needed after the type of procedure and the specific reason
|
Within the first 30-days from the procedure.
|
Overall Survival
Periodo de tiempo: Through study completion, an average of 1 year.
|
Assessment of mortality in the post-operative period
|
Through study completion, an average of 1 year.
|
Aorta Related Survival
Periodo de tiempo: Through study completion, an average of 1 year.
|
Assessment of mortality in the post-operative period related to aortic procedure or aortic related death.
|
Through study completion, an average of 1 year.
|
Freedom from reintervention
Periodo de tiempo: Through study completion, an average of 1 year.
|
Time from procedure to the first aortic related/procedure related reintervention
|
Through study completion, an average of 1 year.
|
Freedom from Vessel Instability
Periodo de tiempo: Through study completion, an average of 1 year.
|
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
|
Through study completion, an average of 1 year.
|
Freedom from Major Endoleaks
Periodo de tiempo: Through study completion, an average of 1 year.
|
Time from procedure to the presence of high-flow endoleak (TypeI/III) and from endoleak that required reintervention
|
Through study completion, an average of 1 year.
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Gallitto E, Faggioli G, Spath P, Pini R, Mascoli C, Ancetti S, Stella A, Abualhin M, Gargiulo M. The risk of aneurysm rupture and target visceral vessel occlusion during the lead period of custom-made fenestrated/branched endograft. J Vasc Surg. 2020 Jul;72(1):16-24. doi: 10.1016/j.jvs.2019.08.273. Epub 2020 Feb 13.
- Gallitto E, Gargiulo M, Faggioli G, Pini R, Mascoli C, Freyrie A, Ancetti S, Stella A. Impact of iliac artery anatomy on the outcome of fenestrated and branched endovascular aortic repair. J Vasc Surg. 2017 Dec;66(6):1659-1667. doi: 10.1016/j.jvs.2017.04.063. Epub 2017 Sep 6.
- Maurel B, Resch T, Spear R, Roeder B, Bracale UM, Haulon S, Mastracci TM. Early experience with a modified preloaded system for fenestrated endovascular aortic repair. J Vasc Surg. 2017 Apr;65(4):972-980. doi: 10.1016/j.jvs.2016.09.045.
- Spanos K, Kolbel T, Kubitz JC, Wipper S, Konstantinou N, Heidemann F, Rohlffs F, Debus SE, Tsilimparis N. Risk of spinal cord ischemia after fenestrated or branched endovascular repair of complex aortic aneurysms. J Vasc Surg. 2019 Feb;69(2):357-366. doi: 10.1016/j.jvs.2018.05.216. Epub 2018 Oct 29.
- Bertoglio L, Loschi D, Grandi A, Melloni A, Bilman V, Melissano G, Chiesa R. Early Limb Reperfusion Using Routinely Preloaded Fenestrated Stent-graft Designs for Complex Endovascular Aortic Procedures. Cardiovasc Intervent Radiol. 2020 Dec;43(12):1868-1880. doi: 10.1007/s00270-020-02596-1. Epub 2020 Jul 19.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- MPSRA
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .